REFERENCES
1. Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.
Ann Oncol. 2014;25(10):1889-1900.
2. Burrows F, Shivani M, Wang Z, Chan S, Gilardi M, Gutkind S. Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma
. Europ J Cancer. 2020;138:S43-S44.
3. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different.
Genes Cancer. 2011;2(3):216-231.
4. Rampias T, Giagini A, Siolos S, et al. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Clin Cancer Res. 2014;20(11):2933-2946.
5. Kodaz H, Kostek O, Hacioglu, MB, et al. Frequency of Ras mutations (Kras, Nras, Hras) in human solid cancer.
Eurasian J Med Oncol. 2017;1(1):1-7.
6. Chau NG, Li YY, Jo VY, et al. Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma
. Clin Cancer Res. 2016;22(12):2939-2949.
7. Dilmaghani NA, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Bashash D. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
IUBMB Life. 2021;73(4):618-642.
8. Marquard FE, Jucker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Biochem Pharmacol. 2020;172:113729.